REDHILL B.S.ADR 10/IL-,01 Forum: Community User: MeisterYoda1

600k Aktien stehen nun zu einem Zinssatz von 88% zur Verfügung....die Shorties ziehen sich also zurück - oder bereiten den ganz großen Angriff vor!

Das Volumen ist ganz schön mickrig....interessiert sich keiner mehr für den Bumms?

Ich bleibe hier dabei..

Mr. Ben-Asher continued: “With an urgent need to develop broad-spectrum, host-directed antivirals for pandemic preparedness, RedHill is driving forward its opaganib and RHB-107 COVID-19 and other antiviral programs. We are currently in advanced discussions regarding external non-dilutive development funding for RHB-107 and are in the process of finalizing RHB-107’s inclusion in a key platform study to be supported by a U.S. government arm. Both opaganib and RHB-107 continue to demonstrate the variant-agnostic value of being host-directed, demonstrating in vitro inhibition of the Omicron BA.5 sub-variant in testing conducted at the University of Tennessee. We are also delighted with the grant of a new COVID-19 treatment patent for opaganib. Beyond COVID-19, we have established several cooperative research projects, with both government and non-government entities, to evaluate opaganib and RHB-107 across multiple targets, including influenza, which opaganib recently demonstrated in vitro efficacy against, Ebola, and others. We are also pleased with the important recognition of EU Orphan Designation for RHB-204, currently in Phase 3 study as the first stand-alone standard of care first-line therapy for NTM disease, and for which prospective partnership discussions are advancing across multiple territories.”

Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “Quarter two, and our expectations for the second half of the year, reflect significant operational and strategic progress by RedHill in the face of persistent negative biotech sector sentiment. Our commercial team is streamlined, with much reduced operational spend, and continues to rapidly grow new prescriptions. It is this growth, at this stage in its lifecycle, that is making Movantik such a valuable and saleable asset, and which has led Talicia to be the most prescribed branded agent by the Gastroenterology community, on track to become the most prescribed branded H. pylori therapy in 2023. With increased gross sales, we are applying substantial efforts to improving gross-to-net yields, using multiple parallel mechanisms. We are fully committed to refining our pre-pandemic debt structure in a way that helps us rapidly grow our business both organically and externally, through the intended sale of Movantik and the planned addition of new revenue-generating products currently under discussions. We continue to work relentlessly to maximize the value of our products and optimize our business. As such, the cost-reduction program we implemented is expected to deliver its major impact in the second half of the year.”

· Corporate update: Substantial impact from cost-reduction program expected in 2H/22, supporting planned improvement in cash from operations; Discussions advancing with HCR regarding default status and repayment of loan; Movantik sale process advancing rapidly aimed at satisfying outstanding obligations under the HCR credit agreement; Multiple RHB-204 out-licensing discussions progressing; Addition of significant revenue-generating GI products ongoing; Litigation against Kukbo initiated without counter-arguments from Kukbo and a favorable judgement is expected within weeks, strengthening the balance sheet significantly if collected · R&D update: Opaganib and RHB-107 COVID-19 programs advancing; RHB-107 development funding and potential inclusion in a key platform trial, as well as other external non-dilutive financing, well advanced. Both broad-acting, host-directed, antiviral candidates subject of ongoing discussions with the U.S. government for pandemic preparedness and other government programs, and both demonstrated in vitro inhibition of Omicron BA.5 sub-variant. Opaganib granted new COVID-19 treatment patent and, separately, demonstrated in vitro efficacy against Influenza; RHB-204 for NTM disease granted EU Orphan Designation

Hätte doch schlimmer kommen können...

RedHill Biopharma (Nasdaq: RDHL) today reported its second quarter 2022 financial results and operational highlights, restatement of first quarter 2022 financial results and the provision of third quarter 2022 estimates. · Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance of $43.2 million as of June 30, 2022; Restated Q1/22: Net revenues of $13.1 million; Q3/22: Net revenues estimated to be between $16.5 million to $18.5 million; Operating loss estimated to be in the range of $5.5 million to $7.5 million; Q3/22 cash flow from operating activities is estimated positive for U.S operations, before interest payments · Commercial update: Upward trajectory continues with Talicia® and Movantik® new prescriptions up 11.2% and 4.0% over Q1/22, respectively; Commercial PBM win for Talicia improves coverage for 58 million more lives – Talicia® on track to become the most prescribed branded H. pylori therapy in 2023; Market leader, Movantik®, also anticipated to benefit from PAMORA class growth trends; With strong increases in gross sales, primary focus on improving gross-to-net yields

die Zahlen sind doch schon nicht mehr so wichtig. Entweder sie verkaufen Movantik (und retten sich aus der Kreditklemme) , dann sehen die Zahlen sicherlich ganz anders aus, oder der Verkauf scheitert und dann sind sie wohl pleite. Im Text wieder viel BlaBla und eine Menge von Andeutungen.

Aber Veru geht ab! Wir sind die doofen die auf den alten zahnlosen Gaul gewettet haben

Mich wundert, dass hier gerade kaum am Kurs gerüttelt wird....so toll sind die Zahlen ja nicht....

Und wo geht die Reise nun hin?

https://www.redhillbio.com/investors/financial-filings/sec-filings/sec-filings-details/default.aspx?FilingId=16180059

@Genesys: Ob das gut ist oder schlecht ist können wir nicht bewerten oder? Mal was neues aus der Chartkugel: Wir haben nun die letzte Chance die kleine Unterstützung bei 0,61 zu verteidigen...schaffen wir es nicht, werden wir direkt zur 0,50-0,52 und darunter ein neues Allzeittief erreichen.

@Bunga: Leider wurde beantragt, die Dokumente nicht weiter zu veröffentlichen. Auf der Trello-Seite kann man zwar sehen, dass sich etwas bewegt aber die Schriftstücke nicht mehr einsehen.